Roopal Thakkar
Fortuna: 12 M $ al 31/05/2026
Fortuna: 12 M $ al 31/05/2026
Roopal Thakkar is currently Chief Scientific Officer, Executive VP-R&D at AbbVie, Inc. since 2024.
Formerly, Dr. Thakkar was Chief Medical Officer & Senior Vice President at Global Therapeutics, Inc. Education includes an undergraduate degree from the University of Michigan and a doctorate from Wayne State University School of Medicine.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
ABBVIE, INC. 0 % | 06/03/2026 | 55.374 ( 0 % ) | 12 M $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| ABBVIE INC. | Director Técnico/Científico/I+D | 01/01/2003 |
| Empresas | Cargo | Fin |
|---|---|---|
Global Therapeutics, Inc.
Global Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Specializes in advanced medical devices | Director Técnico/Científico/I+D | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
AbbVie, Inc.
AbbVie, Inc. Pharmaceuticals: MajorHealth Technology Engages in the research and development, manufacturing, commercialization & sale of immunology medicines and therapies | Health Technology |
Global Therapeutics, Inc.
Global Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Specializes in advanced medical devices | Commercial Services |
University of Michigan
University of Michigan Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Wayne State University School of Medicine
Wayne State University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.